Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Analysts

Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) has been assigned an average rating of "Hold" from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $5.43.

A number of research firms have recently issued reports on FATE. Wedbush restated a "neutral" rating and set a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, March 6th. Stifel Nicolaus lowered their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company cut their price objective on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. StockNews.com cut Fate Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, March 11th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, March 6th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in Fate Therapeutics by 18.2% during the third quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company's stock worth $6,431,000 after purchasing an additional 283,080 shares during the period. Barclays PLC boosted its holdings in shares of Fate Therapeutics by 245.3% during the 3rd quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company's stock worth $1,485,000 after buying an additional 301,389 shares during the period. SG Americas Securities LLC grew its stake in Fate Therapeutics by 30.6% in the 4th quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 10,511 shares during the last quarter. Walleye Capital LLC raised its holdings in Fate Therapeutics by 263.5% in the 3rd quarter. Walleye Capital LLC now owns 67,609 shares of the biopharmaceutical company's stock worth $237,000 after acquiring an additional 49,009 shares during the period. Finally, Geode Capital Management LLC lifted its position in Fate Therapeutics by 0.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company's stock worth $7,905,000 after acquiring an additional 10,863 shares during the last quarter. Institutional investors and hedge funds own 97.54% of the company's stock.

Fate Therapeutics Price Performance

NASDAQ FATE traded up $0.12 on Monday, hitting $1.06. 1,451,132 shares of the stock were exchanged, compared to its average volume of 2,314,479. The company's 50-day moving average price is $1.06 and its two-hundred day moving average price is $1.85. Fate Therapeutics has a 52-week low of $0.66 and a 52-week high of $5.96. The company has a market capitalization of $121.47 million, a price-to-earnings ratio of -0.64 and a beta of 2.41.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its quarterly earnings results on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.57 million. Equities analysts predict that Fate Therapeutics will post -1.63 EPS for the current fiscal year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.